🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to scientists.

An International Public Health Issue

The sexually transmitted infection are increasing around the world, with figures suggesting over 82 million instances annually. Especially elevated rates are observed in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce therapeutic options currently available.”

Health officials are increasingly worried about the increase in drug-resistant strains. The global health body has designated it as a "priority pathogen". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Gain Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in recent days for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Scientists hope that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in concurrent days. This treatment, which is also used to treat urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This authorization signifies a significant shift in the management of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Research Study Data and Worldwide Availability

According to findings published in a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This establishes an equal footing with the current standard treatment, which involves two antibiotics. The research involved hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the ability to register and commercialise the drug in many low-income and middle-income countries.

Doctors directly involved have shared hope. Access to a one-pill regimen such as this is seen as a "game-changer" for gonorrhoea control. This is deemed vital to alleviate the strain of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.